Michel Lanteri-Minet is an expert in Neurology at Centre Hospitalier Universitaire de Nice (France). As of October 2026, ScienceLeadR ranks Michel Lanteri-Minet in the top 1% of experts worldwide for Headache Disorders, Migraine Disorders and Headache. Michel Lanteri-Minet has authored 312 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 1 of them ongoing. SLR score: 1,233 (community average: 125). How the SLR is computed.

LeadR Profile

Michel Lanteri-Minet Centre Hospitalier Universitaire de Nice France
1 233 ScienceLeadR Reputation 1233
Network Map

Neurology

Subspecialties: Pharmacy - Public Health - Preventive Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026

Source: PubMed

Centre Hospitalier Universitaire de Nice

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 312

Citations

Citations: 20 458 1st author: 47 Last author: 59 Unique author: 27


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Opioid use, disability, and patient-reported cognitive impairment in migraine: Multi-country results from the Chronic Migraine Epidemiology and Outcomes-International Study.
PMID 42856050 — headache, epidemiology, multiple chronic conditions, migraine disorders, cognitive dysfunction, analgesics, cognition disorders, therapeutics, headache disorders
Headache20260
Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study.
PMID 42828704 — pain, migraine disorders, therapeutics
Neurol Ther20260
Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.
PMID 42533319 — headache, registries, safety, antibodies, migraine disorders, antibodies, monoclonal, therapeutics
J Headache Pain20261
Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry.
PMID 42457526 — registries, safety, blood, blood pressure, migraine disorders, drug-related side effects and adverse reactions, therapeutics, neurology
Rev Neurol (Paris)20260
Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.
PMID 42403306 — headache, vaccines, covid-19 vaccines, cluster headache, vaccination, covid-19, pharmacovigilance
Headache20260

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 1 Sub-Investigator: 1

By phase:

N/A 8
Phase 3 6
Phase 4 6
Phase 2 3
Phase 1 1

By status:

Completed 20
Recruiting 2
Active not recruiting 1
Unknown 1

By type:

Interventional 21
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 3
multicentric5to9 2
multicentricup10 14

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Efficacy of Light Therapy in Treatment of Chronic Cluster Headache
NCT06540651 — headache, cluster headache, phototherapy, proof of concept study, therapeutics
N/ARecruiting2025

LeadR Networks

Main global connection map